Novo Nordisk: A Rare Second Chance (NYSE:NVO)

In early August 2025, I not only increase my position in Novo Nordisk ( NVO ) significantly. Following second quarter earnings I also published my last article about Novo Nordisk A/S ( NVO ) and arguedMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small ...